Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2007 2
2008 3
2009 3
2010 4
2011 1
2013 2
2014 4
2015 7
2016 8
2017 5
2018 4
2019 5
2020 3
2021 5
2022 2
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Somatic mutations affect key pathways in lung adenocarcinoma.
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Ding L, et al. Nature. 2008 Oct 23;455(7216):1069-75. doi: 10.1038/nature07423. Nature. 2008. PMID: 18948947 Free PMC article.
The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. ...
The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably E …
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA. Vokes NI, et al. J Thorac Oncol. 2022 Jun;17(6):779-792. doi: 10.1016/j.jtho.2022.02.011. Epub 2022 Mar 21. J Thorac Oncol. 2022. PMID: 35331964 Free PMC article.
Reduced progression-free survival on later-line osimertinib in 33 patients was associated with MET, APC, and ERBB4 alterations. Further investigation of the effect of TP53 alterations revealed an association with worse outcomes even in patients with good initial radiograph …
Reduced progression-free survival on later-line osimertinib in 33 patients was associated with MET, APC, and ERBB4 alterations. Furth …
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Sequist LV, et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816960 Corrected and republished. Clinical Trial.
PURPOSE: The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HE …
PURPOSE: The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family …
Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L, Wang Y, Tian J, Song W, Li L, Che G. Tian L, et al. Int J Mol Sci. 2023 Mar 30;24(7):6520. doi: 10.3390/ijms24076520. Int J Mol Sci. 2023. PMID: 37047493 Free PMC article.

In addition, patients in cluster2 were with high tumor mutational burden (TMB) and numerous significant mutated oncogene and tumor suppressor genes, such as WNT10B, ERBB4, SMARCA4, TP53, and CDKN2A (p < 0.001). A total of 19 genes were mostly related to the prognosis of

…
In addition, patients in cluster2 were with high tumor mutational burden (TMB) and numerous significant mutated oncogene and tumor suppresso …
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
Jiang Y, Fang X, Xiang Y, Fang T, Liu J, Lu K. Jiang Y, et al. Curr Oncol. 2023 May 28;30(6):5337-5349. doi: 10.3390/curroncol30060405. Curr Oncol. 2023. PMID: 37366888 Free PMC article. Review.
Afatinib, the world's first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK …
Afatinib, the world's first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGF …
Tastin promotes non-small-cell lung cancer progression through the ErbB4, PI3K/AKT, and ERK1/2 pathways.
Yue A, Chen M, Dai S, Zhang Y, Wei W, Fan L, Wang F, Zhang F, Yu H, Lu Y, Lei Y. Yue A, et al. Exp Biol Med (Maywood). 2023 Mar;248(6):519-531. doi: 10.1177/15353702221147566. Epub 2023 Jan 23. Exp Biol Med (Maywood). 2023. PMID: 36691332 Free PMC article.
Silencing of tastin inhibited the proliferative and migratory abilities of NSCLC cells. Bioinformatic analysis suggested that tastin interacts with ErbB4. The PI3K/AKT and ERK1/2 downstream pathways were suppressed in tastin-deficient cells. ...
Silencing of tastin inhibited the proliferative and migratory abilities of NSCLC cells. Bioinformatic analysis suggested that tastin interac …
Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ, Denessiouk K, Johnson MS, Elenius K. Kurppa KJ, et al. Oncogene. 2016 Mar 10;35(10):1283-91. doi: 10.1038/onc.2015.185. Epub 2015 Jun 8. Oncogene. 2016. PMID: 26050618
Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4-ErbB2 heterodimers. ...Interestingly, serum starvation of NIH 3T3 cells expressing the ERBB4 mutants only moderately increased the …
Consistently, the mutations enhanced ErbB4 dimerization and increased the trans activation in ErbB4 homodimers and ErbB4 …
Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.
Guyard A, Danel C, Théou-Anton N, Debray MP, Gibault L, Mordant P, Castier Y, Crestani B, Zalcman G, Blons H, Cazes A. Guyard A, et al. Respir Res. 2017 Jun 15;18(1):120. doi: 10.1186/s12931-017-0605-y. Respir Res. 2017. PMID: 28619094 Free PMC article.
Mutations were identified in TP53 (n = 20), MET (n = 4), BRAF (n = 3), FGFR3, PIK3CA, PTEN, STK11 (n = 2), SMAD4, CTNNB1, DDR2, ERBB4, FBXW7 and KRAS (n = 1) genes. No ALK and ROS1 expressions were identified. ...
Mutations were identified in TP53 (n = 20), MET (n = 4), BRAF (n = 3), FGFR3, PIK3CA, PTEN, STK11 (n = 2), SMAD4, CTNNB1, DDR2, ERBB4 …
[Mechanism of action and preclinical development of afatinib].
Diz Taín P, González AL, García-Palomo A. Diz Taín P, et al. Med Clin (Barc). 2016 Apr;146 Suppl 1:7-11. doi: 10.1016/S0025-7753(16)30257-3. Med Clin (Barc). 2016. PMID: 27426242 Review. Spanish.
This is an irreversible inhibitor of the ErbB family, acting on EGFR (HER1, ErbB1), ErbB2 (HER2) and ErbB4 (HER4). Covalent attachment to cysteine residues in the catalytic domain of EGFR, HER2 and ErbB4 inhibits the tyrosine kinase activity (TKIs) of these receptor …
This is an irreversible inhibitor of the ErbB family, acting on EGFR (HER1, ErbB1), ErbB2 (HER2) and ErbB4 (HER4). Covalent attachmen …
Analysis of ERBB4 mutations and expression in japanese patients with lung cancer.
Tomizawa K, Suda K, Onozato R, Kuwano H, Yatabe Y, Mitsudomi T. Tomizawa K, et al. J Thorac Oncol. 2010 Nov;5(11):1859-61. doi: 10.1097/JTO.0b013e3181f1c433. J Thorac Oncol. 2010. PMID: 20975381 Free article.
However, we detected no mutations in extracellular or kinase domains of ERBB4. There was no significant difference in the clinicopathologic characteristics including prognosis of patients with high or low expression of ERBB4. The clinical significance of ERBB4 …
However, we detected no mutations in extracellular or kinase domains of ERBB4. There was no significant difference in the clinicopath …
57 results